# US 2023/0406913 A1 · Method for treating sars-cov-2 infectious disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406913 A1
- Document ID: US20230406913A1
- Status: Published application
- Kind: A1
- Application number: 18/181,881
- Filed: 2023-03-10
- Published: 2023-12-21
- Earliest claimed: 2022-03-11
- Assignees: Research & Business Foundation Sungkyunkwan University
- Applicants: Research & Business Foundation Sungkyunkwan University
- Inventors: Wonhwa LEE
- Web page: https://patentgrep.com/patent/US20230406913A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/24: against cytokines, lymphokines or interferons
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/701: {Specific hybridization probes}
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/56983: {Viruses}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/16: Aptamers
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2333/475: Assays involving growth factors
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are a composition for diagnosis of SARS-CoV-2 infectious disease, a diagnostic kit, a method for providing information for diagnosis, a method for screening a therapeutic agent, and a composition for prevention or treatment, wherein it is expected that the diagnosis or prognostic prediction of the severity of SARS-CoV-2 infectious disease can be attained and the control of expression and activity of TOX, which is a marker, can be advantageously used in the development of a therapeutic agent for SARS-CoV-2 infectious disease.

## Claims

### Claim 1

A method for treating SARS-CoV-2 infectious disease, the method comprising administering to a subject a composition comprising an agent for inhibiting expression or activity of thymocyte selection associated high mobility group box (TOX) protein or a polynucleotide encoding TOX protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent for inhibiting expression or activity of TOX protein or a polynucleotide encoding TOX protein is an antibody or antigen-binding fragment thereof, a small-molecule compound, siRNA, shRNA, miRNA, or a combination thereof.

### Claim 3

A method for treating a severe SARS-CoA-2 patient, the method comprising:
measuring the protein level or mRNA expression level of thymocyte selection associated high mobility group box (TOX) in a biological sample isolated from a SARS-CoV-2 infected patient;
comparing the measured protein level or mRNA expression level of TOX with that of a normal control group; and
administering a composition for treatment of SARS-CoV-2 infection to a SARS-CoV-2 infected patient, from which a biological sample with a higher protein level or mRNA expression level of TOX than the normal control group is isolated.

### Claim 4 (depends on 3)

The method of claim 3, wherein the biological sample is at least one selected from the group consisting of blood, plasma, serum, saliva, nasal mucus, sputum, capsular fluid, amniotic fluid, ascites, cervical or vaginal discharge, urine, and cerebrospinal fluid.

### Claim 5 (depends on 3)

The method of claim 3, wherein the composition for treatment of SARS-CoV-2 infection comprises remdesivir, regdanvimab, ritonavir-boosted nirmatrelvir, molnupiravir, dexamethasone, hydrocortisone, prednisolone, methylprednisolone, tocilizumab, baricitinib, convalescent plasma, casirivimab, imdevimab, sotrovimab, bamlanivimab, etesevimab, or a combination thereof.

### Claim 6 (depends on 3)

The method of claim 3, wherein the composition for treatment of SARS-CoV-2 infection comprises an agent for inhibiting expression or activity of thymocyte selection associated high mobility group box (TOX) protein or a polynucleotide encoding TOX protein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the agent for inhibiting expression or activity of TOX protein or a polynucleotide encoding TOX protein is an antibody, a small-molecule compound, siRNA, shRNA, or a combination thereof.
